| Project Acronym | ISIDORe II |
|---|---|
| Funding Programme | Horizon Europe |
| Budget | €10,456,496.25 |
| Coordinator | European Research Infrastructure on Highly Pathogenic Agents (ERINHA) |
| Project Duration | 1 June 2026 – 31 May 2029 |
Project overview
ISIDORe II: Integrated Services for Infectious Disease Outbreak Research II is the continuation of ISIDORe and aims to strengthen Europe’s research infrastructure capacity for pandemic preparedness and response. The project provides coordinated transnational and virtual access to research services supporting work on epidemic- and pandemic-prone pathogens, medical countermeasures, FAIR data, Open Science, and One Health.
The project consolidates a more strategic and integrated access model, combining infectious disease-focused research infrastructures with transversal infrastructures offering technologies such as imaging, omics, structural biology, drug discovery, ex vivo models, and clinical research support. ISIDORe II will use a unified service catalogue and access platform to help users identify and access the most relevant services across the consortium.
ISIDORe II also focuses on improving the scientific, ethical, regulatory, and translational value of user projects, embedding FAIR data stewardship and strengthening alignment with European and global preparedness actors such as HERA, ECDC, WHO, DURABLE, and the BE READY NOW Partnership.
Consortium
The ISIDORe II consortium brings together a broad network of European research infrastructures and scientific organisations with complementary expertise across infectious diseases, translational medicine, clinical research, biobanking, imaging, structural biology, data management, epidemiology, and medical countermeasure development.
The consortium integrates high-containment facilities, transnational access services, translational and clinical research infrastructures, and advanced technology platforms to provide coordinated support for epidemic and pandemic preparedness research. Through this multidisciplinary and cross-infrastructure approach, ISIDORe II aims to accelerate infectious disease research and strengthen Europe’s long-term preparedness and response capacity.
EATRIS’ role in the project
EATRIS contributes to ISIDORe II as the translational medicine infrastructure partner, supporting access to services that help move infectious disease research outputs toward medical countermeasure development and clinical translation.
EATRIS leads activities in WP15, including the collection of data, feedback, and dissemination of TNA project results and regulatory advice and development strategy support. This includes early regulatory assessment, EMA and national authority alignment, development planning, IMPD support, marketing authorisation considerations, and clinical trial authorisation support.
EATRIS also contributes to clinical trial planning activities led by ECRIN, helping ensure that ISIDORe II user projects have a clear and supported route from regulatory readiness toward clinical implementation.
